Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data

OBJECTIVES: Tofacitinib is a Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ulcerative colitis, and has been investigated in psoriasis (PsO). Routine pharmacovigilance of an ongoing, open-label, blinded-endpoint, tofacitinib RA trial (Study A3921...

Descripción completa

Detalles Bibliográficos
Autores principales: Mease, Philip, Charles-Schoeman, Christina, Cohen, Stanley, Fallon, Lara, Woolcott, John, Yun, Huifeng, Kremer, Joel, Greenberg, Jeffrey, Malley, Wendi, Onofrei, Alina, Kanik, Keith S, Graham, Daniela, Wang, Cunshan, Connell, Carol, Valdez, Hernan, Hauben, Manfred, Hung, Eric, Madsen, Ann, Jones, Thomas V, Curtis, Jeffrey R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Treatment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7569391/
https://www.ncbi.nlm.nih.gov/pubmed/32759265
http://dx.doi.org/10.1136/annrheumdis-2019-216761

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7569391/
https://www.ncbi.nlm.nih.gov/pubmed/32759265
http://dx.doi.org/10.1136/annrheumdis-2019-216761

Ejemplares similares